首页 | 本学科首页   官方微博 | 高级检索  
     


Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized,double-blind,placebo-controlled phase 3 trial
Authors:Linong Ji MD  Jinmiao Lu PhD  Leili Gao MD  Changjiang Ying MD  Jiao Sun MD  Jie Han MS  Wenhua Zhao MS  Yunming Gao MS  Kun Wang MD  Xin Zheng MD  Daosheng Xie MS  Juping Ding MS  Jiahong Zhao MD  Qiang Yu PhD  Tong Wang PhD
Affiliation:1. Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China;2. CGeneTech Co., Ltd, Suzhou, China;3. Department of Endocrinology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;4. Department of Endocrinology, Huadong Hospital Affiliated to Fudan University, Shanghai, China;5. Department of Endocrinology, Hebei Petro China Central Hospital, Langfang, China;6. Department of Endocrinology, Pepole's Hospital of Changzhi City, Changzhi, China;7. Department of Endocrinology, The Second Pepole's Hospital of Lianyungang, Lianyungang, China;8. Department of Endocrinology, Nanjing Jiangning Hospital, Nanjing, China;9. Department of Endocrinology, Beijing Boai Hospital, Beijing, China;10. Beijing Noahpharm Medical Technology Co., Ltd, Beijing, China
Abstract:
Keywords:cetagliptin  dipeptidyl peptidase-4 inhibitor  DPP-4  type 2 diabetes  T2D
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号